Lung Cancer Clinical Trials

⁃ 1）Aged ≥18 years; 2) Subjects with histologically or cytologically confirmed advanced solid tumors who have failed standard therapy, are intolerant to standard therapy, or have no options of standard of care. During cohort expansion, subjects will be enrolled as follows: Cohort 1: SCLC subjects who failed or were intolerant to at least one prior platinum-containing chemotherapy regimen; Cohort 2: Subjects with DLL3-positive malignant solid tumors who failed standard therapy, are intolerant to standard therapy, or have no options of standard of care.

⁃ 3\) At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1); 4) ECOG score of 0 or 1; 5) Life expectancy ≥3 months; 6) Laboratory parameters meeting the following criteria:

• Neutrophil count ≥1.5×109/L;

• Platelet count ≥100×109/L;

• Hemoglobin ≥9 g/dL;

• Total bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN (In cases with liver metastases: total bilirubin ≤3×ULN and ALT/AST ≤5×ULN);

• Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min;

• International Standardized Ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN.

⁃ a. Fertile males and females must use reliable contraception throughout the study period and for 9 months after the last dose. Females aged 18-60 years must have negative blood pregnancy results within 7 days before the first dose.

⁃ 7\) Understand and voluntarily sign the informed consent form (ICF).